proxyvotesnow.com

Home › Companies › aTyr Pharma, Inc. › 2025-2026

aTyr Pharma, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings. Page generated 04 October 2026.

  • 7Reported items
  • 105Asset managers
  • 809Fund votes
  • 2026-05-11Meeting date

Proxy season: 2025-2026

Explore aTyr Pharma, Inc. in the interactive database Compare manager voting policies

How asset managers voted at the aTyr Pharma, Inc. 2025-2026 meeting

Each item below shows how the 105 asset managers that disclosed a aTyr Pharma, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of aTyr Pharma, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on an advisory basis, the compensation of the Company's named executive officers;

SECTION 14A SAY-ON-PAY VOTES

Combines 3 wordings of this item as funds reported it.

99.6% fund support · no official result

FOR 99.6%

The 103 asset managers below cast 99.6% of the shares they voted on this item FOR (47,420,541 for, 179,446 against).

FOR: 47,420,541 (99.6%)AGAINST: 179,446 (0.4%)
Largest asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers;” at aTyr Pharma, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity19,945,8210 00For
Federated Hermes16,441,5760 00For
BlackRock2,278,075232 00For
Vanguard2,155,1981 00For
GEODE CAPITAL MANAGEMENT, LLC2,040,0350 00For
State Street915,7673,071 00For
Wilkinson Global Asset Management LLC819,5500 00For
Charles Schwab419,2710 00For
Northern Trust347,0672,812 00For
MELLON INVESTMENTS Corp230,9530 00For
Nuveen226,2310 00For
TIAA192,4020 00For
Goldman Sachs139,3940 00For
AQR132,0190 00For
Equitable102,1740 00For
MARSHALL WACE, LLP89,1030 00For
Russell Investments88,5200 00For
Dimensional083,139 00Against
Lincoln Financial67,1000 00For
AllianceBernstein64,4800 00For
QUANTITATIVE MASTER SERIES LLC60,5000 00For
T. Rowe Price49,7780 00For
BANK OF AMERICA NA46,5360 00For
Global X44,0890 00For
AIG/SunAmerica43,7700 00For

Showing the 25 largest of 103 asset managers. See all 103 in the interactive database.

2. To elect three Class II directors, as nominated by the Company's Board of Directors (the "Board of Directors"), to hold office until the 2029 annual meeting of stockholders or until their successors are duly elected and qualified: Eric Benevich

DIRECTOR ELECTIONS

Combines 4 wordings of this item as funds reported it.

100% fund support · no official result

FOR 99.9%

The 35 asset managers below cast 100% of the shares they voted on this item FOR (20,525,550 for, 0 against).

FOR: 20,525,550 (100.0%)ABSTAIN: 8,686 (0.0%)
Largest asset managers voting on “To elect three Class II directors, as nominated by the Company's Board of Directors (the "Board of Directors")” at aTyr Pharma, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Federated Hermes8,220,7880 00For
Fidelity7,759,7040 00For
Vanguard2,033,4120 00For
BlackRock1,606,8820 00For
Charles Schwab208,5340 00For
TIAA192,4020 00For
Equitable102,1740 00For
Lincoln Financial67,1000 00For
QUANTITATIVE MASTER SERIES LLC60,5000 00For
Global X44,0890 00For
AIG/SunAmerica43,7700 00For
Goldman Sachs41,4490 00For
Bridge Builder Trust19,2040 00For
DWS13,3110 00For
SEI13,0000 00For
Nationwide11,8880 00For
John Hancock11,4680 00For
Blackstone Alternative Investment Funds10,8000 00For
Principal9,7770 00For
Voya9,0300 00For
Calvert8,8810 00For
T. Rowe Price8,5180 00For
ProShares8,3130 00For
Venerable Variable Insurance Trust7,2050 00For
State Street4,6870 00For

Showing the 25 largest of 35 asset managers. See all 35 in the interactive database.

3. To elect three Class II directors, as nominated by the Company's Board of Directors (the "Board of Directors"), to hold office until the 2029 annual meeting of stockholders or until their successors are duly elected and qualified: Jane A. Gross, Ph.D.

DIRECTOR ELECTIONS

Combines 4 wordings of this item as funds reported it.

100% fund support · no official result

FOR 99.1%

The 35 asset managers below cast 100% of the shares they voted on this item FOR (20,366,206 for, 0 against).

FOR: 20,366,206 (99.2%)ABSTAIN: 168,030 (0.8%)
Largest asset managers voting on “To elect three Class II directors, as nominated by the Company's Board of Directors (the "Board of Directors")” at aTyr Pharma, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Federated Hermes8,220,7880 00For
Fidelity7,759,7040 00For
Vanguard2,029,4350 3,9770For
BlackRock1,606,8820 00For
Charles Schwab208,5340 00For
TIAA192,4020 00For
Equitable65,2940 36,8800For
Lincoln Financial67,1000 00For
QUANTITATIVE MASTER SERIES LLC60,5000 00For
Global X44,0890 00For
AIG/SunAmerica00 43,7700Abstain
Goldman Sachs41,4490 00For
Bridge Builder Trust19,2040 00For
DWS00 13,3110Abstain
SEI13,0000 00For
Nationwide11,8880 00For
John Hancock00 11,4680Abstain
Blackstone Alternative Investment Funds00 10,8000Abstain
Principal00 9,7770Abstain
Voya00 9,0300Abstain
Calvert00 8,8810Abstain
T. Rowe Price8,5180 00For
ProShares00 8,3130Abstain
Venerable Variable Insurance Trust7,2050 00For
State Street4,6870 00For

Showing the 25 largest of 35 asset managers. See all 35 in the interactive database.

4. To elect three Class II directors, as nominated by the Company's Board of Directors (the "Board of Directors"), to hold office until the 2029 annual meeting of stockholders or until their successors are duly elected and qualified: Timothy P. Coughlin

DIRECTOR ELECTIONS

Combines 4 wordings of this item as funds reported it.

100% fund support · no official result

FOR 99.9%

The 35 asset managers below cast 100% of the shares they voted on this item FOR (20,521,067 for, 0 against).

FOR: 20,521,067 (99.9%)ABSTAIN: 13,169 (0.1%)
Largest asset managers voting on “To elect three Class II directors, as nominated by the Company's Board of Directors (the "Board of Directors")” at aTyr Pharma, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Federated Hermes8,220,7880 00For
Fidelity7,759,7040 00For
Vanguard2,029,4360 3,9760For
BlackRock1,606,8820 00For
Charles Schwab208,5340 00For
TIAA192,4020 00For
Equitable102,1740 00For
Lincoln Financial67,1000 00For
QUANTITATIVE MASTER SERIES LLC60,5000 00For
Global X44,0890 00For
AIG/SunAmerica43,7700 00For
Goldman Sachs41,4490 00For
Bridge Builder Trust19,2040 00For
DWS13,3110 00For
SEI13,0000 00For
Nationwide11,8880 00For
John Hancock11,4680 00For
Blackstone Alternative Investment Funds10,8000 00For
Principal9,7770 00For
Voya9,0300 00For
Calvert8,8810 00For
T. Rowe Price8,5180 00For
ProShares8,3130 00For
Venerable Variable Insurance Trust7,2050 00For
State Street4,6870 00For

Showing the 25 largest of 35 asset managers. See all 35 in the interactive database.

5. To approve an amendment to the aTyr Pharma, Inc. 2015 Stock Option and Incentive Plan, as amended;

COMPENSATION

Combines 4 wordings of this item as funds reported it.

98% fund support · no official result

FOR 98%

The 35 asset managers below cast 98% of the shares they voted on this item FOR (20,215,434 for, 318,802 against).

FOR: 20,215,434 (98.4%)AGAINST: 318,802 (1.6%)
Largest asset managers voting on “To approve an amendment to the aTyr Pharma, Inc. 2015 Stock Option and Incentive Plan, as amended;” at aTyr Pharma, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Federated Hermes8,220,7880 00For
Fidelity7,759,7040 00For
Vanguard2,033,4102 00For
BlackRock1,606,8820 00For
Charles Schwab208,5340 00For
TIAA0192,402 00Against
Equitable102,1740 00For
Lincoln Financial67,1000 00For
QUANTITATIVE MASTER SERIES LLC60,5000 00For
Global X44,0890 00For
AIG/SunAmerica043,770 00Against
Goldman Sachs41,4490 00For
Bridge Builder Trust19,2040 00For
DWS013,311 00Against
SEI13,0000 00For
Nationwide11,8880 00For
John Hancock011,468 00Against
Blackstone Alternative Investment Funds010,800 00Against
Principal09,777 00Against
Voya09,030 00Against
Calvert8,8810 00For
T. Rowe Price08,518 00Against
ProShares08,313 00Against
Venerable Variable Insurance Trust7,2050 00For
State Street4,6870 00For

Showing the 25 largest of 35 asset managers. See all 35 in the interactive database.

6. To approve an amendment to the Company's Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 170,000,000 to 340,000,000 shares; and

CAPITAL STRUCTURE

Combines 4 wordings of this item as funds reported it.

99.9% fund support · no official result

FOR 99.9%

The 35 asset managers below cast 99.9% of the shares they voted on this item FOR (20,531,009 for, 3,227 against).

FOR: 20,531,009 (100.0%)AGAINST: 3,227 (0.0%)
Largest asset managers voting on “To approve an amendment to the Company's Restated Certificate of Incorporation to increase the number of autho” at aTyr Pharma, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Federated Hermes8,220,7880 00For
Fidelity7,759,7040 00For
Vanguard2,030,6922,720 00For
BlackRock1,606,8820 00For
Charles Schwab208,5340 00For
TIAA192,4020 00For
Equitable102,1740 00For
Lincoln Financial67,1000 00For
QUANTITATIVE MASTER SERIES LLC60,5000 00For
Global X44,0890 00For
AIG/SunAmerica43,7700 00For
Goldman Sachs41,4490 00For
Bridge Builder Trust19,2040 00For
DWS13,3110 00For
SEI13,0000 00For
Nationwide11,8880 00For
John Hancock11,4680 00For
Blackstone Alternative Investment Funds10,8000 00For
Principal9,7770 00For
Voya9,0300 00For
Calvert8,8810 00For
T. Rowe Price8,5180 00For
ProShares8,3130 00For
Venerable Variable Insurance Trust7,2050 00For
State Street4,6870 00For

Showing the 25 largest of 35 asset managers. See all 35 in the interactive database.

7. To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026;

AUDIT-RELATED

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

FOR 100%

The 35 asset managers below cast 100% of the shares they voted on this item FOR (20,534,236 for, 0 against).

FOR: 20,534,236 (100.0%)
Largest asset managers voting on “To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Com” at aTyr Pharma, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Federated Hermes8,220,7880 00For
Fidelity7,759,7040 00For
Vanguard2,033,4120 00For
BlackRock1,606,8820 00For
Charles Schwab208,5340 00For
TIAA192,4020 00For
Equitable102,1740 00For
Lincoln Financial67,1000 00For
QUANTITATIVE MASTER SERIES LLC60,5000 00For
Global X44,0890 00For
AIG/SunAmerica43,7700 00For
Goldman Sachs41,4490 00For
Bridge Builder Trust19,2040 00For
DWS13,3110 00For
SEI13,0000 00For
Nationwide11,8880 00For
John Hancock11,4680 00For
Blackstone Alternative Investment Funds10,8000 00For
Principal9,7770 00For
Voya9,0300 00For
Calvert8,8810 00For
T. Rowe Price8,5180 00For
ProShares8,3130 00For
Venerable Variable Insurance Trust7,2050 00For
State Street4,6870 00For

Showing the 25 largest of 35 asset managers. See all 35 in the interactive database.

Largest aTyr Pharma, Inc. shareholders voting in 2025-2026

Ranked by the number of aTyr Pharma, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 98,051,212 shares outstanding at the time of that meeting.

Top aTyr Pharma, Inc. shareholders by shares voted, 2025-2026
#Asset manager % of shares outstanding
1Fidelity 20.34%
2Federated Hermes 16.77%
3BlackRock 2.32%
4Vanguard 2.20%
5GEODE CAPITAL MANAGEMENT, LLC 2.08%
6State Street 0.94%
7Wilkinson Global Asset Management LLC 0.84%
8Charles Schwab 0.43%
9Northern Trust 0.36%
10MELLON INVESTMENTS Corp 0.24%

Reported aTyr Pharma, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

aTyr Pharma, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder % outstanding Disclosure
FMR (Fidelity) 15.00% 13F
1001 Liberty Avenue 8.68% DEF14A
Federated Hermes, Inc. 8.68% 13G
BlackRock 6.57% 13F
Vanguard Group 5.06% 13F
Geode Capital 2.43% 13F
State Street 1.79% 13F
Millennium Management 1.67% 13F
Morgan Stanley 1.43% 13F
Two Sigma 1.17% 13F

Percentages above are of 98,051,212 shares outstanding, as reported by aTyr Pharma, Inc. on its Form 10-Q dated 2026-05-11 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from aTyr Pharma, Inc.’s 10-Q dated 2026-05-11. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At aTyr Pharma, Inc.'s shareholder meeting held 2026-05-11, in the 2025-2026 proxy season, 105 asset managers reported how they voted in their SEC Form N-PX filings, covering 809 separate fund positions. Their filings are grouped here into 7 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. No official Form 8-K vote tally has been matched to this meeting, so this page states no certified outcome for its most widely held ballot item. On that item — To approve, on an advisory basis, the compensation of the Company's named executive officers; — the reporting funds cast 99.6% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

aTyr Pharma, Inc. proxy season coverage: 2025-2026 (this page).